Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano

García-Gómez, Francisco Javier; García-Solís, David; Luis-Simón, F.J.; Marín-Oyaga, V.; Carrillo, Fátima; Mir, Pablo; Vázquez-Albertino, R.

doi:10.1016/j.remn.2013.02.009

Cited by 35 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For confirmation of the DVR analysis, we also performed a paired t-test in Statistical Parametric Mapping software (SPM8; Welcome Department of Cognitive Neurology, University College, London, UK), implemented in Matlab (MathWorks, Natick, Massachusetts). Images were initially normalized using the ioflupane template developed by García-Gómez et al [ 25 ]. For our preliminary study, scans from the NAC group were evaluated using a paired t test between the pre and post NAC scans with the threshold set at p<0.05 and minimum of 50 pixel cluster.…”

Section: Methodsmentioning

confidence: 99%

N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data

et al. 2016

View full text Add to dashboard Cite

BackgoundThe purpose of this study was to assess the biological and clinical effects of n-acetyl-cysteine (NAC) in Parkinson’s disease (PD).MethodsThe overarching goal of this pilot study was to generate additional data about potentially protective properties of NAC in PD, using an in vitro and in vivo approach. In preparation for the clinical study we performed a cell tissue culture study with human embryonic stem cell (hESC)-derived midbrain dopamine (mDA) neurons that were treated with rotenone as a model for PD. The primary outcome in the cell tissue cultures was the number of cells that survived the insult with the neurotoxin rotenone. In the clinical study, patients continued their standard of care and were randomized to receive either daily NAC or were a waitlist control. Patients were evaluated before and after 3 months of receiving the NAC with DaTscan to measure dopamine transporter (DAT) binding and the Unified Parkinson’s Disease Rating Scale (UPDRS) to measure clinical symptoms.ResultsThe cell line study showed that NAC exposure resulted in significantly more mDA neurons surviving after exposure to rotenone compared to no NAC, consistent with the protective effects of NAC previously observed. The clinical study showed significantly increased DAT binding in the caudate and putamen (mean increase ranging from 4.4% to 7.8%; p<0.05 for all values) in the PD group treated with NAC, and no measurable changes in the control group. UPDRS scores were also significantly improved in the NAC group (mean improvement of 12.9%, p = 0.01).ConclusionsThe results of this preliminary study demonstrate for the first time a potential direct effect of NAC on the dopamine system in PD patients, and this observation may be associated with positive clinical effects. A large-scale clinical trial to test the therapeutic efficacy of NAC in this population and to better elucidate the mechanism of action is warranted.Trial RegistrationClinicalTrials.gov NCT02445651

show abstract

Section: Methodsmentioning

confidence: 99%

N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Between-groups (PD vs CG) differences were evaluated by univariate General Linear Model, considering age and gender as nuisance variables. Statistical threshold was set at p<0.05 18, 22 .Statistical Parametric Mapping (SPM8 Wellcome Department of Imaging Neuroscience; http://www.fil.ion.ucl.ac.uk/spm/); 123 I-FP-CIT template from 30 healthy controls 36 was used for normalization process. Individual 123 I-FP-CIT data were realigned, spatially normalized to 123 I-FP-CIT template in Montreal Neurological Institute space and smoothed (3D Gaussian filter with 8 mm Full Width at Half Maximum).…”

Section: Methodsmentioning

confidence: 99%

Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging

et al. 2017

View full text Add to dashboard Cite

Background 123I-FP-CIT (DaTSCAN®) SPECT imaging is widely used to study neurodegenerative parkinsonism, with the evaluation of presynaptic dopamine transporter (DAT) in striatal regions. Beyond DAT, 123I-FP-CIT may be also considered for other monoaminergic systems, in particular serotonin transporter (SERT). Independent Component Analysis (ICA) implemented in Source-Based Morphometry (SBM), a multivariate approach, represents an alternative method to explore monoaminergic neurotransmission, studying the relationship among voxels, and grouping them into “metabolic” neural networks. Methods One-hundred forty-three subjects (84 with Parkinson’s disease (PD) and 59 control individuals (CG)) underwent DATSCAN® imaging. The 123I-FP-CIT binding was evaluated by the multivariate SBM approach, as well as by region-of-interest (ROI) (caudate/putamen) (BRASS software) and whole-brain voxelwise univariate (Statistical Parametric Mapping, SPM) approaches. Results As compared to univariate approaches (BRASS and SPM), which only demonstrated striatal 123I-FP-CIT binding reduction in the PD group, SBM identified six sources of non-artifactual origin, including basal ganglia and cortical regions as well as brainstem. Among them, three sources (basal ganglia and cortical regions) presented loading scores (as index of 123I-FP-CIT binding) significantly different between PD and CG. Notably, even though not significantly different between PD and CG, the remaining three non-artifactual sources were characterized by a predominant frontal, brainstem and occipito-temporal involvement. Discussion The concept of source blind separation by the application of ICA (as implemented in SBM) represents a feasible approach to be considered in 123I-FP-CIT (DaTSCAN®) SPECT imaging. Taking advantage of this multivariate analysis, specific patterns of variance can be identified (involving either striatal or extrastriatal regions) that could be useful in differentiating neurodegenerative parkinsonisms.

show abstract

“…[ 18 F]FDOPA PET and [ 123 I]FP-CIT SPET templates were used as markers of the dopamine synthesis capacity (DDC, dopa decarboxylase enzymatic rate) and the dopamine transporter (DAT) respectively. The templates are freely available at the NITRC website ( http://www.nitrc.org/projects/spmtemplates/ ) [ 12 ]. A template for [ 11 C]Raclopride PET data was obtained by averaging healthy subjects data that have been previously published [ 13 ] and used as D 2 /D 3 receptor density marker.…”

Section: Application To Case Studiesmentioning

confidence: 99%

MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas

et al. 2016

View full text Add to dashboard Cite

IntroductionBrain-wide mRNA mappings offer a great potential for neuroscience research as they can provide information about system proteomics. In a previous work we have correlated mRNA maps with the binding patterns of radioligands targeting specific molecular systems and imaged with positron emission tomography (PET) in unrelated control groups. This approach is potentially applicable to any imaging modality as long as an efficient procedure of imaging-genomic matching is provided. In the original work we considered mRNA brain maps of the whole human genome derived from the Allen human brain database (ABA) and we performed the analysis with a specific region-based segmentation with a resolution that was limited by the PET data parcellation. There we identified the need for a platform for imaging-genomic integration that should be usable with any imaging modalities and fully exploit the high resolution mapping of ABA dataset.AimIn this work we present MENGA (Multimodal Environment for Neuroimaging and Genomic Analysis), a software platform that allows the investigation of the correlation patterns between neuroimaging data of any sort (both functional and structural) with mRNA gene expression profiles derived from the ABA database at high resolution.ResultsWe applied MENGA to six different imaging datasets from three modalities (PET, single photon emission tomography and magnetic resonance imaging) targeting the dopamine and serotonin receptor systems and the myelin molecular structure. We further investigated imaging-genomic correlations in the case of mismatch between selected proteins and imaging targets.

show abstract

Elaboración de una plantilla de SPM para la normalización de imágenes de SPECT con 123I-Ioflupano

Cited by 35 publications

References 11 publications

N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data

N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data

Source-Based Morphometry Multivariate Approach to Analyze [123I]FP-CIT SPECT Imaging

MENGA: A New Comprehensive Tool for the Integration of Neuroimaging Data and the Allen Human Brain Transcriptome Atlas

Contact Info

Product

Resources

About